메뉴 건너뛰기




Volumn 20, Issue 7, 2014, Pages 1925-1934

Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; FIGITUMUMAB; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; SOMATOMEDIN C RECEPTOR; TAXOID;

EID: 84898724863     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1869     Document Type: Article
Times cited : (40)

References (45)
  • 2
    • 70749101076 scopus 로고    scopus 로고
    • Steroid hormone receptors in prostate cancer: A hard habit to break?
    • Attard G, Cooper CS, de Bono JS. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 2009;16:458-62.
    • (2009) Cancer Cell , vol.16 , pp. 458-462
    • Attard, G.1    Cooper, C.S.2    De Bono, J.S.3
  • 3
    • 79959282824 scopus 로고    scopus 로고
    • Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients
    • Attard G, de Bono JS. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clin Cancer Res 2011;17:3867-75.
    • (2011) Clin Cancer Res , vol.17 , pp. 3867-3875
    • Attard, G.1    De Bono, J.S.2
  • 4
    • 4744337716 scopus 로고    scopus 로고
    • Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
    • Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
    • (2004) N Engl J Med , vol.351 , pp. 1513-1520
    • Petrylak, D.P.1    Tangen, C.M.2    Hussain, M.H.3    Lara Jr., P.N.4    Jones, J.A.5    Taplin, M.E.6
  • 5
    • 4744366279 scopus 로고    scopus 로고
    • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    • on behalf of the TAX 327 Investigators
    • Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al., on behalf of the TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
    • (2004) N Engl J Med , vol.351 , pp. 1502-1512
    • Tannock, I.F.1    De Wit, R.2    Berry, W.R.3    Horti, J.4    Pluzanska, A.5    Chi, K.N.6
  • 6
    • 77957682309 scopus 로고    scopus 로고
    • Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised openlabel trial
    • on behalf of the TROPIC Investigators
    • de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al., on behalf of the TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised openlabel trial. Lancet 2010;376:1147-54.
    • (2010) Lancet , vol.376 , pp. 1147-1154
    • De Bono, J.S.1    Oudard, S.2    Ozguroglu, M.3    Hansen, S.4    Machiels, J.P.5    Kocak, I.6
  • 7
    • 79957443342 scopus 로고    scopus 로고
    • Abiraterone and increased survival in metastatic prostate cancer
    • on behalf of the COU-AA-301 Investigators
    • de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al., on behalf of the COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
    • (2011) N Engl J Med , vol.364 , pp. 1995-2005
    • De Bono, J.S.1    Logothetis, C.J.2    Molina, A.3    Fizazi, K.4    North, S.5    Chu, L.6
  • 8
    • 84866770294 scopus 로고    scopus 로고
    • Increased survival with enzalutamide in prostate cancer after chemotherapy
    • on behalf of the AFFIRM Investigators
    • Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al., on behalf of the AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.
    • (2012) N Engl J Med , vol.367 , pp. 1187-1197
    • Scher, H.I.1    Fizazi, K.2    Saad, F.3    Taplin, M.E.4    Sternberg, C.N.5    Miller, K.6
  • 9
    • 84865834363 scopus 로고    scopus 로고
    • Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA)
    • abstr LBA4512
    • Parker C, Nilsson S, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol 2012;30:(suppl; abstr LBA4512).
    • J Clin Oncol 2012 , vol.30 , Issue.SUPPL.
    • Parker, C.1    Nilsson, S.2    Heinrich, D.3    O'Sullivan, J.M.4    Fossa, S.D.5    Chodacki, A.6
  • 10
    • 77955066199 scopus 로고    scopus 로고
    • Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    • on behalf of the IMPACT Study Investigators
    • Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al., on behalf of the IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
    • (2010) N Engl J Med , vol.363 , pp. 411-422
    • Kantoff, P.W.1    Higano, C.S.2    Shore, N.D.3    Berger, E.R.4    Small, E.J.5    Penson, D.F.6
  • 11
    • 78149465086 scopus 로고    scopus 로고
    • Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer
    • Massoner P, Ladurner-Rennau M, Eder IE, Klocker H. Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer. Br J Cancer 2010;103: 1479-84.
    • (2010) Br J Cancer , vol.103 , pp. 1479-1484
    • Massoner, P.1    Ladurner-Rennau, M.2    Eder, I.E.3    Klocker, H.4
  • 12
    • 1942436958 scopus 로고    scopus 로고
    • Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis
    • Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53.
    • (2004) Lancet , vol.363 , pp. 1346-1353
    • Renehan, A.G.1    Zwahlen, M.2    Minder, C.3    O'Dwyer, S.T.4    Shalet, S.M.5    Egger, M.6
  • 13
    • 53749097826 scopus 로고    scopus 로고
    • Insulin-like growth factors, their binding proteins, and prostate cancer risk: Analysis of individual patient data from 12 prospective studies
    • Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008;149:461-71, W83-W88.
    • (2008) Ann Intern Med , vol.149
    • Roddam, A.W.1    Allen, N.E.2    Appleby, P.3    Key, T.J.4    Ferrucci, L.5    Carter, H.B.6
  • 14
    • 84860391606 scopus 로고    scopus 로고
    • Plasma and tissue insulin-like growth factor-I receptor (IGFIR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: A review
    • Ozkan EE. Plasma and tissue insulin-like growth factor-I receptor (IGFIR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. Mol Cell Endocrinol 2011;344:1-24.
    • (2011) Mol Cell Endocrinol , vol.344 , pp. 1-24
    • Ozkan, E.E.1
  • 15
    • 33947495794 scopus 로고    scopus 로고
    • Insulin-like growth factor-related signaling and cancer development
    • Pollak M. Insulin-like growth factor-related signaling and cancer development. Recent Results Cancer Res 2007;174:49-53.
    • (2007) Recent Results Cancer Res , vol.174 , pp. 49-53
    • Pollak, M.1
  • 16
    • 84857640868 scopus 로고    scopus 로고
    • The insulin and insulin-like growth factor receptor family in neoplasia: An update
    • Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012;12:159-69.
    • (2012) Nat Rev Cancer , vol.12 , pp. 159-169
    • Pollak, M.1
  • 17
    • 79951524532 scopus 로고    scopus 로고
    • Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgen-independent progression
    • Takahara K, Tearle H, Ghaffari M, Gleave ME, Pollak M, Cox ME, et al. Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgen-independent progression. Prostate 2011;71:525-37.
    • (2011) Prostate , vol.71 , pp. 525-537
    • Takahara, K.1    Tearle, H.2    Ghaffari, M.3    Gleave, M.E.4    Pollak, M.5    Cox, M.E.6
  • 18
    • 0035881876 scopus 로고    scopus 로고
    • In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR)
    • Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M, et al. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 2001;61:6276-80.
    • (2001) Cancer Res , vol.61 , pp. 6276-6280
    • Nickerson, T.1    Chang, F.2    Lorimer, D.3    Smeekens, S.P.4    Sawyers, C.L.5    Pollak, M.6
  • 19
    • 9244242088 scopus 로고    scopus 로고
    • Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model
    • Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L, et al. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004;64:8620-9.
    • (2004) Cancer Res , vol.64 , pp. 8620-8629
    • Krueckl, S.L.1    Sikes, R.A.2    Edlund, N.M.3    Bell, R.H.4    Hurtado-Coll, A.5    Fazli, L.6
  • 20
    • 0028113415 scopus 로고
    • Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
    • Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474-8.
    • (1994) Cancer Res , vol.54 , pp. 5474-5478
    • Culig, Z.1    Hobisch, A.2    Cronauer, M.V.3    Radmayr, C.4    Trapman, J.5    Hittmair, A.6
  • 21
    • 20144386856 scopus 로고    scopus 로고
    • Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871
    • Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005;11:2063-73.
    • (2005) Clin Cancer Res , vol.11 , pp. 2063-2073
    • Cohen, B.D.1    Baker, D.A.2    Soderstrom, C.3    Tkalcevic, G.4    Rossi, A.M.5    Miller, P.E.6
  • 22
    • 17144416483 scopus 로고    scopus 로고
    • In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors
    • Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL, et al. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 2005;11:3065-74.
    • (2005) Clin Cancer Res , vol.11 , pp. 3065-3074
    • Wu, J.D.1    Odman, A.2    Higgins, L.M.3    Haugk, K.4    Vessella, R.5    Ludwig, D.L.6
  • 23
    • 35948940097 scopus 로고    scopus 로고
    • An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer
    • Plymate SR, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P, et al. An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer. Clin Cancer Res 2007;13:6429-39.
    • (2007) Clin Cancer Res , vol.13 , pp. 6429-6439
    • Plymate, S.R.1    Haugk, K.2    Coleman, I.3    Woodke, L.4    Vessella, R.5    Nelson, P.6
  • 24
    • 0037326983 scopus 로고    scopus 로고
    • Chemosen-sitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor
    • Hellawell GO, Ferguson DJ, Brewster SF, Macaulay VM. Chemosen-sitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor. BJU Int 2003;91:271-7.
    • (2003) BJU Int , vol.91 , pp. 271-277
    • Hellawell, G.O.1    Ferguson, D.J.2    Brewster, S.F.3    Macaulay, V.M.4
  • 25
    • 77955049754 scopus 로고    scopus 로고
    • The insulin-like growth factor-I receptor inhibitor figitumumab (CP- 751,871) in combination with docetaxel in patients with advanced solid tumours: Results of a phase Ib dose-escalation, open-label study
    • Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L, et al. The insulin-like growth factor-I receptor inhibitor figitumumab (CP- 751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer 2010;103:332-9.
    • (2010) Br J Cancer , vol.103 , pp. 332-339
    • Molife, L.R.1    Fong, P.C.2    Paccagnella, L.3    Reid, A.H.4    Shaw, H.M.5    Vidal, L.6
  • 26
    • 84862575958 scopus 로고    scopus 로고
    • A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer
    • Chi KN, Gleave ME, Fazli L, Goldenberg SL, So A, Kollmannsberger C, et al. A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer. Clin Cancer Res 2012;18:3407-13.
    • (2012) Clin Cancer Res , vol.18 , pp. 3407-3413
    • Chi, K.N.1    Gleave, M.E.2    Fazli, L.3    Goldenberg, S.L.4    So, A.5    Kollmannsberger, C.6
  • 27
    • 0032747375 scopus 로고    scopus 로고
    • Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group
    • Errata in J Clin Oncol 2000;18:2644 and J Clin Oncol 2007;25:1154
    • Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-7. [Errata in J Clin Oncol 2000;18:2644 and J Clin Oncol 2007;25:1154.]
    • (1999) J Clin Oncol , vol.17 , pp. 3461-3467
    • Bubley, G.J.1    Carducci, M.2    Dahut, W.3    Dawson, N.4    Daliani, D.5    Eisenberger, M.6
  • 28
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors
    • European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3    Wanders, J.4    Kaplan, R.S.5    Rubinstein, L.6
  • 29
    • 78049294167 scopus 로고    scopus 로고
    • Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer
    • Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N, et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 2010;70:7992-8002.
    • (2010) Cancer Res , vol.70 , pp. 7992-8002
    • Zhu, M.L.1    Horbinski, C.M.2    Garzotto, M.3    Qian, D.Z.4    Beer, T.M.5    Kyprianou, N.6
  • 30
    • 58149165081 scopus 로고    scopus 로고
    • Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer
    • Erratum in Clin Cancer Res 2009;15:1506
    • de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-9. [Erratum in Clin Cancer Res 2009;15:1506.]
    • (2008) Clin Cancer Res , vol.14 , pp. 6302-6309
    • De Bono, J.S.1    Scher, H.I.2    Montgomery, R.B.3    Parker, C.4    Miller, M.C.5    Tissing, H.6
  • 31
    • 0026581740 scopus 로고
    • Planned versus attained design in phase II clinical trials
    • Green SJ, Dahlberg S. Planned versus attained design in phase II clinical trials. Stat Med 1992;11:853-62.
    • (1992) Stat Med , vol.11 , pp. 853-862
    • Green, S.J.1    Dahlberg, S.2
  • 32
    • 16444367879 scopus 로고    scopus 로고
    • Androgens up-regulate the insulin-like growth factor-1 receptor in prostate cancer cells
    • Pandini C, Mineo R, Frasca F, Roberts CT Jr, Marcelli M, Vigneri R, et al. Androgens up-regulate the insulin-like growth factor-1 receptor in prostate cancer cells. Cancer Res 2005;65:1849-57.
    • (2005) Cancer Res , vol.65 , pp. 1849-1857
    • Pandini, C.1    Mineo, R.2    Frasca, F.3    Roberts Jr., C.T.4    Marcelli, M.5    Vigneri, R.6
  • 33
    • 70349926513 scopus 로고    scopus 로고
    • A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC)
    • Abstract nr 7
    • Small E, Demkow T, Gerritsen WR, Rolland F, Hoskin P, Smith DC, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). In: 2009 Genitourinary Cancers Symposium; 2009 Feb 26-28; Orlando, FL. Abstract nr 7.
    • 2009 Genitourinary Cancers Symposium; 2009 Feb 26-28; Orlando, FL
    • Small, E.1    Demkow, T.2    Gerritsen, W.R.3    Rolland, F.4    Hoskin, P.5    Smith, D.C.6
  • 34
    • 84861690508 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401
    • Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012;30:1534-40.
    • (2012) J Clin Oncol , vol.30 , pp. 1534-1540
    • Kelly, W.K.1    Halabi, S.2    Carducci, M.3    George, D.4    Mahoney, J.F.5    Stadler, W.M.6
  • 35
    • 84873865670 scopus 로고    scopus 로고
    • A phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrateresistant prostate cancer (CRPC): The MAINSAIL trial
    • Presented at the Abstract nr LBA24
    • Petrylak DP, Fizazi K, Sternberg CN, Budnik N, De Wit R, Wiechno J, et al. A phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrateresistant prostate cancer (CRPC): the MAINSAIL trial. Presented at the 37th ESMO Congress; 2012. Vol. 23. p ixe15. Abstract nr LBA24.
    • 37th ESMO Congress; 2012 , vol.23
    • Petrylak, D.P.1    Fizazi, K.2    Sternberg, C.N.3    Budnik, N.4    De Wit, R.5    Wiechno, J.6
  • 36
    • 84876283322 scopus 로고    scopus 로고
    • Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial
    • abstr LBA8
    • Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, et al. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): results from the randomized phase III READY trial. J Clin Oncol 31:2013 (suppl 6; abstr LBA8).
    • (2013) J Clin Oncol , vol.31 , Issue.SUPPL. 6
    • Araujo, J.C.1    Trudel, G.C.2    Saad, F.3    Armstrong, A.J.4    Yu, E.Y.5    Bellmunt, J.6
  • 37
    • 84879786803 scopus 로고    scopus 로고
    • Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): A phase 3, double-blind randomised trial
    • on behalf of the VENICE investigators
    • Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fléchon A, Skoneczna I, et al., on behalf of the VENICE investigators. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 2013;14:760-8.
    • (2013) Lancet Oncol , vol.14 , pp. 760-768
    • Tannock, I.F.1    Fizazi, K.2    Ivanov, S.3    Karlsson, C.T.4    Fléchon, A.5    Skoneczna, I.6
  • 38
    • 84879469745 scopus 로고    scopus 로고
    • Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: Time to learn from past experiences
    • Antonarakis ES, Eisenberger MA. Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. J Clin Oncol 2013;31:1709-12.
    • (2013) J Clin Oncol , vol.31 , pp. 1709-1712
    • Antonarakis, E.S.1    Eisenberger, M.A.2
  • 39
    • 84866707774 scopus 로고    scopus 로고
    • Figitumumab combined with carboplatin and paclitaxel in treatmentnaïve Japanese patients with advanced non-small cell lung cancer
    • Goto Y, Sekine I, Tanioka M, Shibata T, Tanai C, Asahina H, et al. Figitumumab combined with carboplatin and paclitaxel in treatmentnaïve Japanese patients with advanced non-small cell lung cancer. Invest New Drugs 2012;30:1548-56.
    • (2012) Invest New Drugs , vol.30 , pp. 1548-1556
    • Goto, Y.1    Sekine, I.2    Tanioka, M.3    Shibata, T.4    Tanai, C.5    Asahina, H.6
  • 40
    • 0035425234 scopus 로고    scopus 로고
    • Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes
    • Fernández AM, Kim JK, Yakar S, Dupont J, Hernandez-Sanchez C, Castle AL, et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 2001;15: 1926-34.
    • (2001) Genes Dev , vol.15 , pp. 1926-1934
    • Fernández, A.M.1    Kim, J.K.2    Yakar, S.3    Dupont, J.4    Hernandez-Sanchez, C.5    Castle, A.L.6
  • 41
    • 84855262200 scopus 로고    scopus 로고
    • A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer
    • Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, et al. A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer. Oncol Rep 2012;27:3-9.
    • (2012) Oncol Rep , vol.27 , pp. 3-9
    • Friedlander, T.W.1    Weinberg, V.K.2    Huang, Y.3    Mi, J.T.4    Formaker, C.G.5    Small, E.J.6
  • 42
    • 78149475830 scopus 로고    scopus 로고
    • A phase II study of cixutumumab (IMC-A12), a monoclonal antibody (MAb) against the insulin-like growth factor 1 receptor (IGF-IR), monotherapy in metastatic castration-resistant prostate cancer (mCRPC): Feasibility of every 3-week dosing and updated results
    • Presented at the Abstract nr 189
    • Higano CS, Alumkal JJ, Ryan CJ, Yu EY, Beer TM, Fox FE, et al. A phase II study of cixutumumab (IMC-A12), a monoclonal antibody (MAb) against the insulin-like growth factor 1 receptor (IGF-IR), monotherapy in metastatic castration-resistant prostate cancer (mCRPC): feasibility of every 3-week dosing and updated results. Presented at the 2010 ASCO Genitourinary Congress. Abstract nr 189.
    • 2010 ASCO Genitourinary Congress
    • Higano, C.S.1    Alumkal, J.J.2    Ryan, C.J.3    Yu, E.Y.4    Beer, T.M.5    Fox, F.E.6
  • 43
    • 84874452203 scopus 로고    scopus 로고
    • Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant prostate cancer (mCRPC): Results of a phase I pilot study
    • abstr e15081
    • Rathkopf DE, Danila DC, Morris MJ, Slovin SF, Borwick LS, Momen L, et al. Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant prostate cancer (mCRPC): Results of a phase I pilot study. J Clin Oncol 29: 2011 (suppl; abstr e15081).
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Rathkopf, D.E.1    Danila, D.C.2    Morris, M.J.3    Slovin, S.F.4    Borwick, L.S.5    Momen, L.6
  • 44
    • 84887499254 scopus 로고    scopus 로고
    • Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo
    • Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, et al. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther 2013;12:2342-55.
    • (2013) Mol Cancer Ther , vol.12 , pp. 2342-2355
    • Thomas, C.1    Lamoureux, F.2    Crafter, C.3    Davies, B.R.4    Beraldi, E.5    Fazli, L.6
  • 45
    • 80054908957 scopus 로고    scopus 로고
    • Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1
    • Li C, Ao J, Fu J, Lee D-F, Xu J, Lonard D, et al. Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. Oncogene 2011;30:4350-64.
    • (2011) Oncogene , vol.30 , pp. 4350-4364
    • Li, C.1    Ao, J.2    Fu, J.3    Lee, D.-F.4    Xu, J.5    Lonard, D.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.